Edition:
India

Spark Therapeutics Inc (ONCE.OQ)

ONCE.OQ on NASDAQ Stock Exchange Global Select Market

51.53USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$51.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
261,418
52-wk High
$91.75
52-wk Low
$41.06

Chart for

About

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a... (more)

Overall

Beta: --
Market Cap(Mil.): $3,132.52
Shares Outstanding(Mil.): 35.82
Dividend: --
Yield (%): --

Financials

Spark's price for Luxturna blindness gene therapy too high: ICER

The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

13 Jan 2018

UPDATE 1-Spark's price for Luxturna blindness gene therapy too high -ICER

Jan 12 The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

13 Jan 2018

CORRECTED-Spark's planned price for Luxturna gene therapy for rare blindness too high -ICER

Jan 12 The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

13 Jan 2018

BRIEF-ICER Says Spark Therapeutics Gene Therapy Price Too High

* INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW SAYS SPARK THERAPEUTICS LUXTURNA GENE THERAPY PRICE FAR TOO HIGH

12 Jan 2018

Spark to charge $850,000 per patient for blindness gene therapy

Spark Therapeutics Inc said on Wednesday it will charge $850,000 per patient for its breakthrough gene therapy to treat a rare form of blindness, a lower than expected price that the company said reflects patient and insurer concerns about access and cost.

03 Jan 2018

Spark to charge $850,000 per patient for blindness gene therapy

Spark Therapeutics Inc said on Wednesday it will charge $850,000 per patient for its breakthrough gene therapy to treat a rare form of blindness, a lower than expected price that the company said reflects patient and insurer concerns about access and cost.

03 Jan 2018

UPDATE 2-Spark to charge $850,000 per patient for blindness gene therapy

Jan 3 Spark Therapeutics Inc said on Wednesday it will charge $850,000 per patient for its breakthrough gene therapy to treat a rare form of blindness, a lower than expected price that the company said reflects patient and insurer concerns about access and cost.

03 Jan 2018

Spark Therapeutics' vision-loss gene therapy to cost $850,000 per patient

Jan 3 Spark Therapeutics Inc said on Wednesday it would charge $850,000 per patient for its gene therapy to treat a rare form of blindness, lesser than analysts' expectation of around $1 million.

03 Jan 2018

BRIEF-Spark Therapeutics Announces Programs To Improve Patient Access To LUXTURNA

* SPARK THERAPEUTICS ANNOUNCES FIRST-OF-THEIR-KIND PROGRAMS TO IMPROVE PATIENT ACCESS TO LUXTURNA™ (VORETIGENE NEPARVOVEC-RZYL), A ONE-TIME GENE THERAPY TREATMENT

03 Jan 2018

BRIEF-Spark Therapeutics - On Jan 3, 2018, Co Announced Wholesale Acquisition Cost For Luxturna Is $425,000/Dose

* SPARK THERAPEUTICS - ON JAN 3, 2018, CO ANNOUNCED WHOLESALE ACQUISITION COST FOR LUXTURNA (VORETIGENE NEPARVOVEC-RZYL) IS $425,000/DOSE OR PER EYE Source text: (http://bit.ly/2CxDOZr) Further company coverage:

03 Jan 2018

Earnings vs. Estimates